You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
興科蓉醫藥(06833.HK)2023年收益增長11.8%至25.4億元
格隆匯 03-26 23:36

格隆匯3月26日丨興科蓉醫藥(06833.HK)公吿,截至2023年12月31日止年度的年度業績,集團收益增長11.8%至人民幣25.4億元,其中人血白蛋白注射液銷售收益增長約人民幣2.5億元,主要得益於銷售量的增長。報吿期內,公司擁有人應占純利為人民幣4240萬元;每股基本及攤簿盈利為人民幣0.02元(2022年:每股基本及攤薄盈利人民幣0.03元)。董事會決議就截至2023年12月31日止年度宣派末期股息每股普通股0.39港仙(2022年:截至2022年12月31日止年度的末期股息0.98港仙)。

集團致力於持續優化和擴展公司的營銷網絡,這已成為公司發展戰略的關鍵組成部分。集團已建設出一個既強大又精煉的內部銷售團隊,並且集團同時也與眾多專業的第三方推廣服務商保持着密切的合作。

面對市場的快速變化,集團以"靈活機動"和"專業高效"為核心準則,集中精力打造一個能夠迅速響應市場變化、高效執行戰略的營銷團隊。集團對團隊結構進行了全面優化,重視人才的發掘和培養,確保團隊成員能夠不斷進步,適應未來市場的需求。同時,公司進一步完善了團隊的績效管理體系,通過科學合理地分配銷售資源,確保每個產品綫都能獲得適當的關注和投入,提升團隊的整體業務運作效率。

集團將繼續秉承創新和發展的核心價值觀,不斷探索和拓展新的業務領域,同時加強企業內部管理,提高風險控制能力,確保企業的持續健康發展。公司堅定地致力於為股東創造價值,為員工提供良好的職業發展平台,並積極履行企業社會責任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account